Hinterbrandner, Magdalena

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2020 | 2018

2020

Riether, Carsten; Pabst, Thomas; Höpner, Sabine; Bacher, Ulrike; Hinterbrandner, Magdalena; Banz, Yara; Müller, Rouven; Manz, Markus G.; Gharib, Walid H.; Francisco, David; Bruggmann, Remy; van Rompaey, Luc; Moshir, Mahan; Delahaye, Tim; Gandini, Domenica; Erzeel, Ellen; Hultberg, Anna; Fung, Samson; de Haard, Hans; Leupin, Nicolas; ... (2020). Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nature medicine, 26(9), pp. 1459-1467. Springer Nature 10.1038/s41591-020-0910-8

Brigger, Daniel; Riether, Carsten; van Brummelen, Robin; Mosher, Kira I; Shiu, Alicia; Ding, Zhaoqing; Zbären, Noemi; Gasser, Pascal; Guntern, Pascal; Yousef, Hanadie; Castellano, Joseph M; Storni, Federico; Graff-Radford, Neill; Britschgi, Markus; Grandgirard, Denis; Hinterbrandner, Magdalena; Siegrist, Mark; Moullan, Norman; Hofstetter, Wilhelm; Leib, Stephen L.; ... (2020). Eosinophils regulate adipose tissue inflammation and sustain physical and immunological fitness in old age. Nature metabolism, 2(8), pp. 688-702. Springer Nature 10.1038/s42255-020-0228-3

Jaeger-Ruckstuhl, Carla A.; Hinterbrandner, Magdalena; Höpner, Sabine; Correnti, Colin E; Lüthi, Ursina; Friedli, Olivier; Freigang, Stefan; Al Sayed, Mohamad F; Bührer, Elias D.; Amrein, Michael A.; Schürch, Christian M.; Radpour, Ramin; Riether, Carsten; Ochsenbein, Adrian F. (2020). TNIK signaling imprints CD8+ T cell memory formation early after priming. Nature communications, 11(1), p. 1632. Nature Publishing Group 10.1038/s41467-020-15413-7

2018

Riether, Carsten; Pabst, Thomas; Höpner, Sabine; Bacher, Vera; Hinterbrandner, Magdalena; Banz, Yara; Müller, Rouven; Manz, Markus G.; Gharib, Walid H.; Ferreira, David; Bruggmann, Remy; Van Rompaey, Luc; Moshir, Mahan; Delahaye, Tim; Gandini, Domenica; Erzeel, Ellen; Hultberg, Anna; Fung, Samson; De Haard, Hans; Leupin, Nicolas; ... (2 December 2018). 2680 Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial (Unpublished). In: ASCO 2018. 2. Dezember 2018.

Provide Feedback